Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer

Stock Information for Reviva Pharmaceuticals Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.